Shares of NxStage Medical, Inc. (NASDAQ:NXTM) Rally 25.98% - News Watch International Print

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) rose by 25.98% in the past week and 24.16% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 27.57% and the outperformance increases to 24.1% for the last 4 weeks.

Nxstage Medical, Inc. is up 8.24% in the last 3-month period. Year-to-Date the stock performance stands at 0.33%. The company shares have rallied 31.03% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $14.61 and the 200 day moving average is recorded at $16.71. S&P 500 has rallied 7.26% during the last 52-weeks. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares have been rated as hold from 1 Wall Street Analysts. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $13.86 in a transaction dated on July 22, 2015. The total value of the transaction was worth $27,720. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $16.52 and hit $18.27 on the upside , eventually ending the session at $17.99, with a gain of 8.05% or 1.34 points. The heightened volatility saw the trading volume jump to 2,136,981 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $1,141 million. The 52-week low of the share price is at $11.5 . NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. NO COMMENTS LEAVE A REPLY Cancel reply